COMMUNIQUÉS West-GlobeNewswire

-
2024 Canada Gairdner Awards Recognize World-Renowned Scientists for Transformative Contributions to Research Impacting Human Health
11/04/2024 -
LES PRIX CANADA GAIRDNER 2024 RECONNAISSENT DES SCIENTIFIQUES DE RENOMMÉE MONDIALE POUR DES CONTRIBUTIONS TRANSFORMATRICES À LA RECHERCHE AYANT UN IMPACT SUR LA SANTÉ HUMAINE
11/04/2024 -
AVITA Medical Updates Expected First Quarter 2024 Revenue
10/04/2024 -
BrightSpring Health Services Specialty Pharmacy Onco360® Selected as National Pharmacy Partner for Voydeya®
10/04/2024 -
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
10/04/2024 -
Cellectis publie une nouvelle approche d'édition intronique pour le traitement des maladies métaboliques congénitales par des cellules souches hématopoïétiques modifiées
10/04/2024 -
PharmAla Announces Private Placement and Concurrent Debt Settlement
10/04/2024 -
Voting Rights and Shares Capital of the Company
10/04/2024 -
Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
10/04/2024 -
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
10/04/2024 -
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
10/04/2024 -
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024
10/04/2024 -
Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
10/04/2024 -
Epic Bio to Participate in a Fireside Chat at the Canaccord Genuity Genetic Medicine for Generalists
10/04/2024 -
New Nextech Med Spa for Wellness and Weight Loss Software Increases Average Patient Encounter Revenue by 70%
10/04/2024 -
Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program : Eleventh tranche fully issued and paid-up
10/04/2024 -
Data Presented at AACR 2024 Showcase Precede Biosciences’ Power to Impact Precision Medicine from a Simple Blood Test
10/04/2024 -
Raydiant Oximetry Secures FDA Approval for Lumerah Investigational Device Exemption (IDE) Study
10/04/2024 -
OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer
10/04/2024
Pages